Aureon Laboratories announced the introduction of Prostate Px+ to predict prostate cancer progression and disease recurrence at the time of diagnosis. Annual PSA screening has resulted in more men being caught earlier in the disease process than ever before. As a result, each year approximately 186,000 men with newly diagnosed prostate cancer will be assessed as low or intermediate risk, making it harder to determine which men have aggressive disease and which do not.

"Although the majority of prostate cancer cases are detected early and categorized as lower risk, there are a significant number of men within this segment whose tumors will grow aggressively, and jeopardize lives," said Dr. Vijay Aggarwal, President and Chief Executive Officer of Aureon Laboratories. "It is imperative that physicians have access to better tools that will assess disease severity and identify high-risk patients hidden within these lower-risk groups."

Prostate Px+ is based on the results of a large study utilizing data and samples from a cohort of 1,027 men assembled from the Mayo Clinic, Uppsala University, University of Connecticut and Duke University Medical Center. In validation, Aureon’s predictive model identified twice as many high-risk events in low and intermediate risk patients than the best available method.

Release Date: May 19, 2008
Source: Aureon Laboratories